

*Ministerial Approval: July 01, 2010*

The Alberta Health Services shall provide cancer drugs specified in the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents for the treatment of cancer as outlined in Ministerial Order # 10/2009

## DEFINITIONS

"Eligible resident" means a person who:

1. holds a valid certificate of registration under the *Health Insurance Premiums Act*,
2. is registered in the Cancer Registry with a disease classified in the *International Classification of Diseases for Oncology*, and
3. requires cancer drugs to treat cancer.

"Cancer Pharmacy" means the pharmacy at the Cross Cancer Institute and the Tom Baker Cancer Centre, and other pharmacies operated by or for cancer centre as outlined in Ministerial Order #10/2009

Subject to this Ministerial Order, Cancer Drugs may be:

1. administered directly to in-patients or out-patients of Cancer Centres, or
2. sent to:
  - i) other health care providers; or
  - ii) a pharmacy that is owned or operated by or for Alberta Health Services, for administration or provision directly to the patient.

**GROUP 1 DRUG LIST** Cancer Drugs in group 1 of the Schedule may be dispensed by a Cancer Pharmacy pursuant to a prescription written by a person who is authorized by the Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

**GROUP 2 DRUG LIST** Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. The following physicians from the CCI and TBCC are automatically named on all Group 2 drugs contained on the following pages: (CCI: Dr. Heather Au, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Charles Butts, Dr. Quincy Chu, Dr. Neil Chua, Dr. David Fenton, Dr. A.L.A. Fields, Dr. Anil Joy, Dr. Karen King, Dr. Sheryl Koski, Dr. John Mackey, Dr. Karen Mulder, Dr. Scott North, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Jennifer Spratin, Dr. Katia Tonkin, Dr. Robert Turner, Dr. Peter Venner); (TBCC: Dr. Gwyn Bebb, Dr. Vivien Bramwell, Dr. Cynthia Card, Dr. Tina Cheng, Dr. Scott Dowden, Dr. P. Duggan, Dr. Jay Easaw, Dr. Bernie Eigl, Dr. Peter Forsyth, Dr. Michelle Geddes, Dr. Neil Hagen, Dr. Desiree Hao, Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Carolyn Owen, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. James Russell, Dr. Farzana Sayani, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster, Dr. Alfred Wong)

**GROUP 3 DRUG LIST**

Cancer Drugs in group 3 of the Schedule may be dispensed by a Cancer Pharmacy if

(a) the Cancer Drugs are part of a research or clinical drug trial approved by Alberta Health Services and the prescription is written by the principal investigator or co-investigator in charge of the trial, or

(b) the Cancer Drugs are approved for special access by Health Canada and a prescription is written by a Cancer Centre Medical Staff member designated as eligible by Albert Health Services to prescribe special access Cancer Drugs.

Reference: Ministerial Order #10/2009.

**ADMINISTRATION CLASSIFICATION**

CLASSIFICATION DESCRIPTION	DELIVERY SITE	STANDARDS
<p>Basic</p> <ul style="list-style-type: none"> <li>• Protocols including drugs (single agent or in combination) that can be administered with basic knowledge of chemotherapy.</li> <li>• Protocols including vesicants or drugs that are considered highly toxic where significant assessment and evaluation are required.</li> <li>• Protocols for basic clinical trials may be included on a case by case decision.</li> </ul>	<ul style="list-style-type: none"> <li>• Tertiary cancer centre</li> <li>• Associate cancer centre</li> <li>• Community cancer centre</li> </ul>	<ul style="list-style-type: none"> <li>• Medical, nursing and pharmacy staff shall have successfully completed the established ACB chemotherapy training programs.</li> <li>• Nurses will be certified in advanced chemotherapy and central venous catheters.</li> <li>• Pharmacy staff shall be certified in chemotherapy preparation and handling.</li> </ul>
<p>Advanced</p> <ul style="list-style-type: none"> <li>• Protocols including complex clinical trials, investigational drugs, new drugs, drugs requiring complex delivery devices (ex. electronic continuous infusion pumps)</li> <li>• Advanced chemotherapy in Community cancer centres, at this time, refers to medications only. It does not include advanced administration methods (i.e. electronic pumps) or complex clinical trials.</li> </ul>	<ul style="list-style-type: none"> <li>• Tertiary cancer centre</li> <li>• Associate cancer centre</li> </ul> <p>Designated Community cancer centres: Barrhead, Bonnyville, Camrose, Canmore, Drayton Valley, Drumheller, Fort McMurray, High River, Hinton, Lloydminster</p>	<ul style="list-style-type: none"> <li>• As for Basic Classification.</li> <li>• Physicians supervising the complex clinical trials and investigational drug trials must have ready access to diagnostic procedures and data management.</li> <li>• Medical, nursing, and pharmacy staff shall have the knowledge and skill to manage complex delivery devices.</li> </ul>
n/a	<ul style="list-style-type: none"> <li>• Any health care setting</li> <li>• For oral and SC medications</li> <li>• Patient may self-administer</li> </ul>	<ul style="list-style-type: none"> <li>• No special training for health care professional required to administer.</li> </ul>

“Cancer Centre” means the following centres:

- Calgary Health Region Alberta Children’s Hospital
- Peter Lougheed Centre
- Stollery Children’s Hospital
- University of Alberta Hospital
- Tom Baker Cancer Centre, and the following associate and community centres:
  - Lethbridge Cancer Centre
  - Medicine Hat Cancer Centre
  - Drumheller Community Cancer Centre
  - High River Community Cancer Centre
  - Bow Valley Community Cancer Centre
- Cross Cancer Institute, and the following associate and community centres:
  - Central Alberta Cancer Centre (Red Deer)
  - Grande Prairie Cancer Centre
  - Barrhead Community Cancer Centre
  - Bonnyville Community Cancer Centre
  - Camrose Community Cancer Centre
  - Fort McMurray Community Cancer Centre
  - Hinton Community Cancer Centre
  - Peace River Community Cancer Centre
  - Lloydminster Community Cancer Centre
  - Drayton Valley Community Cancer Centre

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ANAGRELIDE	2	capsules		Mar/98 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ANASTROZOLE	1	tablets	<p><b><u>Breast Cancer - Metastatic</u></b></p> <ul style="list-style-type: none"> <li>• For post-menopausal patients with receptor-positive, metastatic breast cancer who have progressed or have experienced severe side effects on prior hormone therapy.</li> </ul>	Apr/03	n/a
			<p><b><u>Breast Cancer - Adjuvant</u></b></p> <ul style="list-style-type: none"> <li>• For <u>adjuvant</u> use in invasive breast cancer patients who are postmenopausal, hormone receptor positive in whom tamoxifen is contraindicated or not tolerated.</li> <li>• As an adjuvant treatment in postmenopausal, hormone receptor positive breast high risk (node positive, high and intermediate risk node negative, Stage IIB/III) cancer patient who has completed primary surgery and chemotherapy (where appropriate) (or other aromatase inhibitor if intolerant to anastrozole)</li> </ul>	Nov/03  May/06	n/a
ASPARAGINASE	1	injectable			Advanced
AZACITIDINE	2	injectable	<p><b><u>Hematology/Lymphoma</u></b></p> <ul style="list-style-type: none"> <li>• For the treatment of patients with MDS with IPSS high-intermediate and high-risk scores or AML with up to 30% blasts and myelodysplastic features.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou</p> <p><b>TBCC</b> Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Stanley Benke, Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. M. Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	May/10	Basic
BCG	1	injectable		Jan/91 Apr/09	Bladder instillation - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BEVACIZUMAB	2	Injectable	<p><b>Colorectal</b></p> <ul style="list-style-type: none"> <li>• In combination with chemotherapy in the treatment of advanced colorectal cancer (indicated for first line therapy, or if bevacizumab naive, second line therapy)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Heather Au, Dr. Charles Butts, Dr. Neil Chua,            Dr. David Fenton, Dr. A.L.A. Fields, Dr. Karen King,            Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Michael Sawyer,            Dr. Andrew Scarfe, Dr. Jennifer Spratlin,            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng,            Dr. Scot Dowden, Dr. Jay Easaw, Dr. Bruce Keith (May 31,            2010 - October 1, 2010), Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Sandy Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. P. Tang,            Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley,            Dr. Alfred Wong</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the GI tumor program or outlined under group 2 drugs on first page</p>	Apr/09	Basic
BICALUTAMIDE	1	tablets		May/97 Apr/09	n/a
BLEOMYCIN	1	injectable			sc test dose, IV push, inf - basic
BLEOMYCIN	2	pump			electronic continuous infusion pump - advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BORTEZOMIB	2	injectable	<p><b>Hematology/Lymphoma</b></p> <ul style="list-style-type: none"> <li>• Relapsed Multiple Myeloma</li> <li>• in the first line treatment of previously untreated Multiple Myeloma who are not candidates for autologous stem cell transplantation (HDT-ASCT)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou</p> <p><b>TBCC</b>            Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. David Holland</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. M. Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Aug/06 May/08	Basic
BUSERELIN	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• Restricted to:               <ul style="list-style-type: none"> <li>• Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>• Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Adjuvant use (3 years post RT).</li> <li>• Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>• In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>• Guidelines for LHRH use in the above stated stages include:               <ul style="list-style-type: none"> <li>• LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a
BUSULFAN	1	tablets			n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CAPECITABINE	2	oral	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>• Metastatic or advanced breast (with or without prior anthracycline exposure)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton,            Dr. Anil Joy, Dr. Karen King, Dr. John Mackey,            Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b>            Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden,            Dr. Bruce Keith (May 31, 2010 - October 1, 2010),            Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk,            Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether,            Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thael,            Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/98 Jul/02 Oct/03 Jan/04	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CAPECITABINE	2	oral	<p><b><u>Gastrointestinal - Colorectal Cancer</u></b></p> <ul style="list-style-type: none"> <li>• Option in first line treatment of advanced or metastatic colorectal cancer.</li> <li>• (instead of 5-Fluouracil and Leucovorin) in combination with Oxaliplatin as palliative treatment for Metastatic colorectal cancer</li> <li>• Adjuvant treatment of colorectal cancer</li> </ul> <p><b><u>Gastrointesinal – Esophagogastric Cancer</u></b></p> <ul style="list-style-type: none"> <li>• in combination with Epirubicin and Cisplatin as first line palliative chemotherapy for patients with locally advanced or Metastatic cancer of the esophagus, gastroesophageal junction or stomach</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Heather Au, Dr. C. Butts, Dr. Neil Chua,            Dr. David Fenton, Dr. A.L.A. Fields, Dr. Karen King,            Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Michael Sawyer,            Dr. Andrew Scarfe, Dr. Jennifer Spratlin,            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng,            Dr. Scot Dowden, Dr. Jay Easaw, Dr. Bruce Keith (May 31,            2010 - October 1, 2010), Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Sandy Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. P. Tang,            Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley,            Dr. A. Wong</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Josh Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p>As recommended by the GI tumour group or outlined under group 2 drugs on first page.</p>	Mar/01  Oct/07  May/10 Oct/07	n/a
CARBOPLATIN	1	injectable		May/85	IV inf. - basic
CARMUSTINE	1	injectable, topical			IV inf. - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CETUXIMAB	2	injectable	<p><b>Head and Neck Cancer</b></p> <ul style="list-style-type: none"> <li>• Locally / regionally advanced head and neck squamous cell carcinoma</li> <li>• Patient has locally or regionally advanced squamous cell carcinoma of the head and neck without distant metastases, and</li> <li>• are over the age of 70 and have Karnofsky Performance score <math>\geq</math> 90, and</li> <li>• cetuximab is used in combination with curative radical radiotherapy, and</li> <li>• recommended dosage is: Initially 400 mg/m<sup>2</sup>, then 250 mg/m<sup>2</sup> weekly for six to seven weeks.</li> <li>• Prescribing limited to written authorization by named physicians: CCI Dr. Q. Chu, Dr. N. Chua, Dr. S. Koski, Dr. J. Mackey TBCC Dr. D. Hao, Dr. M. Webster</li> </ul> <p>As recommended by the Head and Neck tumour group or outlined under group 2 drugs on first page.</p>	Oct/09	Advanced
CHLORAMBUCIL	1	tablets			n/a
CISPLATIN	1	injectable		Mar/90 May/06	IV inf. – basic Intraperitoneal - advanced
CLADRIBINE	2	injectable subcutaneous		Mar/96 Apr/09	IV inf., sc - basic Electronic continuous infusion pump - Advanced
CYCLOPHOSPHAMIDE	1	injectable, tablets			IV push, inf. - basic
CYPROTERONE	1	tablets		May/85	n/a
CYTARABINE	1	injectable			IV push, IT, inf. - basic
CYTARABINE, LIPOSOMAL	3	injectable		Mar/01 Apr/09	IT - advanced
DACARBAZINE	1	injectable			IV inf. - basic
DACTINOMYCIN	1	injectable			IV push - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DASATINIB	2	oral	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• For the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate. Recommendations included the following: <ul style="list-style-type: none"> <li>• for adult patients with chronic phase CML with primary or acquired resistance to imatinib (600 mg/day) at doses of 100 mg per day or 70 mg two times daily</li> <li>• for adult patients with chronic phase CML who progress to accelerated phase on imatinib (600 mg/day). Dosing recommended: 140 mg per day</li> <li>• for adult patients with chronic phase CML who have blast crisis while on imatinib 600 mg/day. Dosing recommended: 140 mg per day</li> <li>• for adult patients with CML who have intolerance to imatinib or have experienced grade 3 or higher toxicities to imatinib</li> <li>• For adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia whose disease is resistant to imatinib-containing chemotherapy (patient must have tried 600 mg/day) or have experienced grade 3 non-hematologic toxicity, or grade 4 hematologic toxicity persisting for more than 7 days to imatinib.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> </li> </ul> <p><b>CCI</b>  Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou</p> <p><b>TBCC</b>  Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thaeell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>Grande Prairie</b>  Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>  Dr. Stanley Benke, Dr. David Holland</p> <p><b>Medicine Hat</b>  Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>  Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma program or outlined under group 2 drugs on first page.</p>	Oct/09	n/a
DAUNORUBICIN	1	injectable			IV push, inf. - basic
DEXAMETHASONE	1	injectable, tablets	<ul style="list-style-type: none"> <li>• Antiemetic use NOT covered.</li> </ul>		n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DOCETAXEL	2	injectable	<u><b>Lung Cancer</b></u> <ul style="list-style-type: none"> <li>• Restricted to second line therapy in patients with advanced or metastatic non-small cell lung cancer with good performance status (ECOG 0-2) and no symptomatic or uncontrolled brain metastases.</li> <li>• Prescribing limited to written authorization by named physicians:  <b>CCI</b>                      Dr. Dick Au, Dr. Charles Butts, Dr. Quincy Chu, Dr. David Fenton, Dr. Anil Joy, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Michael Smylie  <b>TBCC</b>                      Dr. Gwyn Bebb, Dr. Cynthia Card, Dr. Desiree Hao, Dr. Vanessa Krause, Dr. Don Morris, Dr. Dean Ruether                      Dr. Mike Vickers  <b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke  <b>Lethbridge</b>                      Dr. David Holland  <b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. Marc Trudeau  <b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa                      As recommended by the lung tumour program or outlined under group 2 drugs on first page.</li> </ul>	Mar/01 Apr/03	Advanced
			<u><b>Prostate Cancer</b></u> <ul style="list-style-type: none"> <li>• Docetaxel (with prednisone) as first line treatment of hormone refractory prostate cancer</li> <li>• Prescribing limited to written authorization by named physicians:  <b>CCI</b>                      Dr. Scott North, Dr. Peter Venner  <b>TBCC</b>                      Dr. Tina Cheng, Dr. Bernie Eigl, Dr. D. Heng, Dr. Dean Ruether, Dr. Mike Vickers  <b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke  <b>Lethbridge</b>                      Dr. David Holland  <b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. M. Trudeau  <b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa                      As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</li> </ul>	Sept/04	Advanced
			<u><b>Breast Cancer - Metastatic</b></u> <ul style="list-style-type: none"> <li>• Treatment of metastatic breast cancer after a failure of any previous chemotherapy regimen.</li> <li>• As a single agent or in combination, as an option for first line treatment of metastatic breast cancer.</li> <li>• Only one taxane is to be administered to any one patient.</li> </ul>	Jan/96 Mar/01	IV every 3 weeks - Advanced Low dose weekly IV - basic
			<u><b>Breast Cancer - Neoadjuvant</b></u> <ul style="list-style-type: none"> <li>• Following a neoadjuvant anthracycline containing regimen in locally advanced (Stage IIIA or IIIB) breast cancer (either preceding or following surgery).</li> </ul>	Apr/03 Oct/05	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DOCETAXEL	2	injectable	<p><b>Breast Cancer - Adjuvant</b></p> <ul style="list-style-type: none"> <li>For the adjuvant treatment of lymph node positive breast cancer patients and for the adjuvant treatment of lymph node negative (intermediate or high-risk) breast cancer patients</li> <li>Prescribing limited to written authorization by named physicians: CCI Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</li> </ul> <p><b>TBCC</b> Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thaell, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	<p>Apr/03 Sept/04 May/06 Sep/07</p> <p>May/08 Aug/09</p>	
			<p><b>Gynecology</b></p> <ul style="list-style-type: none"> <li>in the treatment of ovarian, primary peritoneal, or fallopian tube carcinoma first line in patients with hypersensitivity to paclitaxel</li> <li>Prescribing limited to written authorization by named physicians: CCI Dr. Dick Au, Dr. Valerie Capstick, Dr. Wylam Faught, Dr. Michael Sawyer, Dr. Alexandra Schepansky, Dr. Helen Steed, Dr. Katia Tonkin</li> </ul> <p><b>TBCC</b> Dr. P. Chu, Dr. Prafull Ghatage, Dr. Jill Nation</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b> Dr. M. Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa As recommended by the gynecology tumour program or outlined under group 2 drugs on first page.</p>	<p>Oct/07</p>	
DOXORUBICIN	1	injectable			IV push – basic Electronic continuous infusion pump - advanced
DOXORUBICIN LIPOSOMAL	2	injectable	<ul style="list-style-type: none"> <li>Kaposi's sarcoma.</li> </ul>	Feb/99	Advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DOXORUBICIN LIPOSOMAL	2	injectable	<p><b>Ovarian - Cancer</b></p> <ul style="list-style-type: none"> <li>• Second or third line treatment of ovarian cancer, fallopian tube carcinoma, and primary peritoneal neoplasms.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Valerie Capstick, Dr. Wylam Faught, Dr. Michael Sawyer, Dr. Alexandra Schepansky, Dr. Helen Steed, Dr. Katia Tonkin</p> <p><b>TBCC</b> Dr. P. Chu, Dr. Prafull Ghatage, Dr. Jill Nation,</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. M. Trudeau</p> <p>As recommended by the gynecology tumour program or outlined under group 2 drugs on first page.</p>	Mar/01 Jul/02	Advanced
EPIRUBICIN	2	injectable	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>• Adjuvant (node positive) and neoadjuvant (Stage II and III) treatment of pre and post menopausal breast cancer patients.</li> <li>• Adjuvant treatment of high risk (as defined by current Alberta Breast Cancer Program Guidelines), lymph node negative breast cancer</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b> Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thaell, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Mar/01 Jul/02 Sept/04	IV push - basic
EPIRUBICIN	3	injectable	<ul style="list-style-type: none"> <li>• Adjuvant treatment in NCIC MA 21 trial</li> <li>• Prescribing limited to written authorization by clinical trial principle investigator(s) or co-investigators</li> </ul>	Oct/03	IV push- basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
EPIRUBICIN	2	injectable	<p><b><u>Gastrointestinal</u></b></p> <ul style="list-style-type: none"> <li>• Used (in combination with Cisplatin and Fluorouracil) in the treatment of locally advanced or metastatic esophagogastric cancer in patients with good performance status.</li> <li>• As neoadjuvant/adjuvant chemotherapy for patients unable to receive standard adjuvant chemoradiotherapy due to an intra-thoracic gastro-esophageal interposition, as treatment for a resected adenocarcinoma of the stomach, esophagus, and/or gastro-esophageal junction.</li> </ul>	Apr/03  Oct/05	IV push- basic
ERLOTINIB	2	tablets	<p><b><u>Lung</u></b></p> <ul style="list-style-type: none"> <li>• For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen and whose EGFR expression status is positive or unknown</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Charles Butts, Dr. Quincy Chu, Dr. David Fenton, Dr. Anil Joy, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Michael Smylie</p> <p><b>TBCC</b> Dr. Gwyn Bebb, Dr. Cynthia Card, Dr. Desiree Hao, Dr. Vanessa Krause, Dr. Don Morris, Dr. Dean Ruether Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p>	Aug/06	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ERWINIA L-ASPARAGINASE	2	injectable	<p><b>Hematology / Lymphoma</b> Tumour Group???</p> <ul style="list-style-type: none"> <li>restricted to use in patients hypersensitive to E. coli asparaginase for remission in acute lymphoblastic leukemia</li> <li>prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou</p> <p><b>CCI (Pediatrics)</b>                      Dr. Sunil Desai, Dr. Paul Grundy, Dr. Kent Stobart, Dr. Beverly Wilson, Dr. M. Spavor</p> <p><b>TBCC</b>                      Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thaell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>TBCC (Pediatrics)</b>                      Dr. Ron A. Anderson, Dr. P. Duggan, Dr. G. Guilcher, Dr. L. Lafay-Cousin, Dr. Victor Lewis, Dr. Aru Narendran, Dr. Douglas Strother</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. Stanley Benke, Dr. David Holland</p> <p><b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the pediatric and hematology lymphoma tumour program:</p>	Feb/10	Advanced
ETOPOSIDE	1	injectable, capsules			IV inf. – basic
EXEMESTANE	1	oral	<p><b>Breast Cancer - Metastatic</b></p> <ul style="list-style-type: none"> <li>For post menopausal patients with receptor positive, advanced/metastatic breast cancer that have progressed or have experienced severe side effects on prior hormone therapy</li> </ul>	Mar/01 Jan/04 Apr/04	n/a
			<p><b>Breast Cancer - Adjuvant</b></p> <ul style="list-style-type: none"> <li>After two to three years of tamoxifen therapy as option for adjuvant treatment of post menopausal patients with primary hormone receptor positive breast cancer (or other aromatase inhibitor if intolerant to exemestane)</li> </ul>	May/06	n/a
FLUDARABINE	2	injectable, tablets		Mar/96 Apr/09	IV inf. - basic
FLUOROURACIL	1	injectable, cream			IV push, inf. - basic
	2	pump	electronic continuous infusion pumps. Baxter (elastomeric) pumps.	Jan/02 Jan/02	Advanced Basic
FLUTAMIDE	1	tablets		May/85 Apr/09	n/a
GEMCITABINE	2	injectable		May/10	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
GOSERELIN	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>Restricted to:                             <ul style="list-style-type: none"> <li>Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Adjuvant use (3 years post RT).</li> <li>Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>Guidelines for LHRH use in the above stated stages include:                             <ul style="list-style-type: none"> <li>LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a
	2	injectable	<p><b>Breast Cancer:</b></p> <ul style="list-style-type: none"> <li>Second line hormonal therapy for recurrent or metastatic disease in either or both estrogen and progesterone receptor positive pre and perimenopausal patients after tamoxifen failure.</li> </ul> <p><b>Breast Cancer Adjuvant:</b></p> <ul style="list-style-type: none"> <li>With or without tamoxifen, as first line adjuvant treatment in pre or peri-menopausal patients with early, hormone receptor positive breast cancer in whom chemotherapy is contraindicated.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b>                      Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether,                      Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thaeil, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. David Holland</p> <p><b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa                      As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/98 Jul/02  Feb/05	n/a
HYDROCORTISONE SODIUM SUCCINATE	1	injectable	<ul style="list-style-type: none"> <li>Intrathecal use only.</li> </ul>		IT – basic
HYDROXYUREA	1	capsules			n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IDARUBICIN	3	injectable		Jul/98 Apr/09	
IFOBAMIDE	1	injectable			IV inf. – basic
IMATINIB	2	tablets	<p><b>Musculoskeletal</b></p> <ul style="list-style-type: none"> <li>• For surgically unresectable or metastatic gastrointestinal stromal tumour (GIST).</li> <li>• Prescribing limited to written authorization by named physicians: CCI: Dr. Quincy Chu, Dr. Karen Mulder, Dr. Robert Turner TBCC: Dr. Vivian Bramwell, Dr. Don Morris, Dr. Mike Vickers</li> </ul> <p><b>Medicine Hat</b> Dr. M. Trudeau <b>Lethbridge</b> Dr. D. Holland <b>Red Deer</b> Dr. Callisto Tarukandirwa As recommended by the musculoskeletal tumour program or outlined under group 2 drugs on first page.</p>	Apr/03	n/a
			<p><b>Hematology/Lymphoma</b></p> <ul style="list-style-type: none"> <li>• Philadelphia-chromosome positive leukemia (including disease situations such as first chronic phase chronic myelogenous leukemia (CML), accelerated phase CML, blast crisis phase CML, acute lymphoblastic leukemia, or other leukemia's that have the characteristic t (9;22) trans location detected by cytogenetics, FISH analysis, or PCR-positive for bcr-abl oncogene)</li> <li>• Prescribing limited to written authorization by named physicians: CCI: Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou TBCC: Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</li> </ul> <p><b>Lethbridge</b> Dr. Chi-Cheong Au, Dr. Stanley Benke, Dr. David Holland <b>Medicine Hat</b> Dr. Jay Easaw, Dr. Marc Trudeau <b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Apr/03 Oct/03	n/a
INTERFERON alpha 2b	1	injectable		Jul/97 Apr/09	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IRINOTECAN	2	injectable		Jan/00 Mar/98 Oct/03 Jul/06 Aug/09	IV inf. – basic
*Note: Loperamide supplied by industry with this agent's use.					
ISOTRETINOIN	2	capsules		Mar/99 Apr/09	n/a
LENALIDOMIDE	2	capsules	<p><b>MDS</b> – for the treatment of anemia due to myelodysplastic syndrome with a deletion of 5q cytogenetic abnormality</p> <p><b>Multiple Myeloma</b></p> <ul style="list-style-type: none"> <li>• Multiple myeloma after at least one prior therapy</li> <li>• Prescribing limited to named physicians WHO ARE REGISTERED IN REVAID PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER:</li> </ul> <p><b>CCI</b> Dr. Andrew Belch, Dr. Neil Chua, Dr. Gregory Dueck, Dr. Loree Larratt, Dr. Robert Turner</p> <p><b>TBCC</b> Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thaell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>Grande Prairie</b> Dr. Marie A. Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Stanley Benke,</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p>	Aug/09  Oct/09	n/a
LETROZOLE	1	tablets	<p><b>Breast Cancer – Metastatic</b></p> <ul style="list-style-type: none"> <li>• First line therapy for hormone receptor positive postmenopausal metastatic breast cancer.</li> </ul> <p><b>Breast Cancer - Adjuvant</b></p> <ul style="list-style-type: none"> <li>• For 3 years after 5 years of Tamoxifen therapy for early stage breast cancer (or another Aromatase inhibitor if intolerant to letrozole)</li> <li>• As an adjuvant treatment in postmenopausal, hormone receptor positive breast high risk (node positive, high and intermediate risk node negative, Stage IIB/III) cancer patient who has completed primary surgery and chemotherapy (where appropriate) (or other aromatase inhibitor if intolerant to letrozole)</li> </ul>	Oct/98 Jul/02 Apr/03  Feb/06  Oct/07	n/a  n/a
LEUCOVORIN CALCIUM	1	injectable, tablets		Jul/92 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
LEUPROLIDE	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• Restricted to: <ul style="list-style-type: none"> <li>• Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>• Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Adjuvant use (3 years post RT).</li> <li>• Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>• In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>• Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> <li>• LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a
LOMUSTINE	1	capsules			n/a
MECHLORETHAMINE	1	injectable, topical			IV push – basic
MEDROXYPROGESTERONE ACETATE	1	tablets			n/a
MEGESTROL ACETATE	1	tablets			n/a
MELPHALAN	1	tablets			n/a
MERCAPTOPURINE	1	tablets			n/a
MESNA	1	injectable			n/a
METHOTREXATE	1	injectable, tablets			IM, IV push, IT, IV inf. – basic
MITOMYCIN	1	injectable	<ul style="list-style-type: none"> <li>• 3rd line for bladder cancer indication</li> </ul>		Bladder instillation, IV push – basic
MITOTANE	1	oral	<ul style="list-style-type: none"> <li>• for use in adrenocortical cancer</li> </ul>	May/08	n/a
MITOXANTRONE	1	injectable		May/85	IV push, inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
(nab)-PACLITAXEL	2	injectable	<p><b>Breast Cancer - Metastatic</b></p> <ul style="list-style-type: none"> <li>patients who have had severe acute infusion reactions with paclitaxel or docetaxel, considered by the treating physician to be due to the vehicle of the taxanes (cremophor and polysorbate80); or patients who have experienced severe toxicity* from previous administration of other taxanes. *severe toxicity could be due to the pre-medications for the administration of the taxane or due to the taxane itself.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b>            Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jan/08 Apr/09	IV-advanced
NILUTAMIDE	1	tablets		Jan/93 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
OXALIPLATIN	2	injectable	<p><b>Oxaliplatin – Colorectal Cancer Metastatic</b></p> <ul style="list-style-type: none"> <li>• Oxaliplatin in conjunction with a fluoropyrimidine (eg 5-Fluorouracil, capecitabine) in the treatment of advanced or metastatic colorectal cancer.</li> </ul> <p><b>Oxaliplatin – Colorectal Cancer Adjuvant</b></p> <ul style="list-style-type: none"> <li>• Oxaliplatin adjuvant therapy for Stage III and high risk Stage II Colorectal Cancer</li> <li>• Prescribing limited to written authorization by named physicians</li> </ul> <p><b>CCI</b>            Dr. Heather Au, Dr. Charles Butts, Dr. Neil Chua,            Dr. David Fenton, Dr. A.L.A. Fields, Dr. Karen King,            Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Michael Sawyer,            Dr. Andrew Scarfe, Dr. Jennifer Spratlin,            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng,            Dr. Scot Dowden, Dr. Jay Easaw, Dr. Bruce Keith (May 31,            2010 - October 1, 2010), Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Sandy Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. P. Tang,            Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley,            Dr. Alfred Wong</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the GI tumor program or outlined under group 2 drugs on first page</p>	<p>Mar 07            Oct/07            Apr/09</p> <p>May/10</p> <p>Mar 07</p>	IV-basic
PACLITAXEL	2	injectable		Dec/98 Apr/09	IV, Intraperitoneal – advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PANITUMUMAB	2	injectable	<p><b>Colorectal Cancer Metastatic</b></p> <ul style="list-style-type: none"> <li>As monotherapy for the treatment of patients with metastatic/advanced colorectal carcinoma with non-mutated (wild-type) K-RAS after failure of fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens. Recommended dosing is 6 mg/kg every 2 weeks until progression.</li> <li>Prescribing limited to written authorization by named physicians</li> </ul> <p><b>CCI</b>            Dr. Heather Au, Dr. Charles Butts, Dr. Neil Chua,            Dr. David Fenton, Dr. A.L.A. Fields, Dr. Karen King,            Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Michael Sawyer,            Dr. Andrew Scarfe, Dr. Jennifer Spratlin,            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng,            Dr. Scot Dowden, Dr. Jay Easaw, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Sandy Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. P. Tang,            Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley,            Dr. Alfred Wong</p> <p><b>Lethbridge</b>            Dr. David Holland</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the GI tumor program or outlined under group 2 drugs on first page</p>	Oct/09	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PEMETREXED	2	injectable	<p><b>Lung and Gastrointestinal</b></p> <ul style="list-style-type: none"> <li>• Pemetrexed (in combination with cisplatin) for use in patients with malignant mesothelioma</li> <li>• for second line treatment of patients with non-small cell lung cancer</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Heather Au, Dr. C. Butts, Dr. Quincy Chu, Dr. David Fenton, Dr. A.L.A. Fields, Dr. A. Joy, Dr. Karen King, Dr. Sheryl Koski, Dr. K. Mulder, Dr. Randeep Sangha, Dr. M. Sawyer, Dr. A. Scarfe, Dr. M. Smylie, Dr. Jennifer Spratlin, Dr. C. Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. W. Blahey, Dr. C. Card, Dr. S. Dowden, Dr. J. Easaw, Dr. D. Hao, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. Vanessa Krause, Dr. S. Lupichuk, Dr. D. Morris, Dr. A.H.G. Paterson, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. T. Thaeil, Dr. Mike Vickers, Dr. B. Walley, Dr. A. Wong</p> <p><b>Grande Prairie</b>            Dr. D. Moreau, Dr. C. Strehlke</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. N. Graham, Dr. Callisto Tarukandirwa</p> <p><b>Lethbridge</b>            Dr. Dave Holland</p> <p>As recommended by the lung or GI tumour group program or outlined under group 2 drugs on first page.</p>	Feb/05  May/08	Basic
PREDNISOLONE SODIUM PHOSPHATE	1	liquid		Nov/96 Apr/09	n/a
PREDNISON	1	tablets			n/a
PROCARBAZINE	1	capsules		Oct/05 Apr/09	n/a
RALTITREXED	2	injectable		Jul/97 Mar/03 Apr/09	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RITUXIMAB	2	injectable	<p><b>Hematology/Lymphoma</b></p> <ul style="list-style-type: none"> <li>• Rituximab plus chemotherapy for patients with follicular, mantle cell, and other CD20+ indolent histology non-Hodgkin's lymphoma who have had no prior treatment with Rituximab</li> <li>• Relapsed or refractory, low-grade or follicular, CD20 positive, B-cell, non-Hodgkin's lymphoma.</li> <li>• In combination with CHOP for aggressive histology B-cell CD20 positive non-Hodgkin's lymphoma (any age or stage).</li> <li>• For Post Transplant Lymphoproliferative Disorders (PTLD).</li> <li>• Maintenance Rituximab for Follicular Lymphoma patients who are in remissions (CR or PR) following chemotherapy +/- Rituxan induction.</li> <li>• extended maintenance therapy for 8 doses in patients with indolent CD-20(+) B cell lymphomas who have recently (within 3 months) responded to systemic therapy and have never previously received maintenance Rituximab</li> <li>• reinduction chemotherapy (including high dose therapy and ASCT) for patients with CD-20(+) Large B cell lymphomas who are in first relapse after at least a 6 month remission following initial chemotherapy (R-Chop) and who are considered potential candidate for high dose therapy and autologous stem cell transplantation (no serious co-morbidities, no CNS lymphoma)</li> <li>• Rituximab in combination with chemotherapy as first-line treatment of chronic lymphocytic leukemia</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Melanie Bodnar, Dr. Neil Chua, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Bruce Ritchie, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Robert Turner, Dr. Nancy Zhou</p> <p><b>TBCC</b>            Dr. Nirar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr Michelle Geddes, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Carolyn Owen, Dr. Dean Ruether, Dr. J. Russell, Dr. Mary Lynn Savoie, Dr. Farzana Sayani, Dr. M. Shafey, Dr. Doug Stewart, Dr. J. Storek, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. David Holland</p> <p><b>Medicine Hat</b>            Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Sept/04  Jan/00  Mar/01 May/04  Apr/03  Mar/07  May/08         May/10	IV – advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SORAFENIB	2	tablets	<p><b>Advanced Hepatocellular Carcinoma</b></p> <ul style="list-style-type: none"> <li>• For patients with Child Pugh Class A advanced hepatocellular carcinoma,</li> <li>• Have ECOG status 0, 1, or 2; and</li> <li>• Patients who have either progressed on trans-arterial chemoembolization (TACE) or are not suitable for the TACE procedure</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Heather Au, Dr. Charles Butts, Dr. Neil Chua,                      Dr. David Fenton, Dr. A.L.A. Fields, Dr. Karen King,                      Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Michael Sawyer,                      Dr. Andrew Scarfe, Dr. Jennifer Spratlin,                      Dr. Clarence Wong</p> <p><b>TBCC</b>                      Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng,                      Dr. Scot Dowden, Dr. Jay Easaw, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. Vanessa Krause,                      Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Sandy Paterson,                      Dr. Dean Ruether, Dr. Doug Stewart, Dr. P. Tang,                      Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley,                      Dr. Alfred Wong</p> <p><b>Lethbridge</b>                      Dr. David Holland</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the GI tumor program or outlined under group 2 drugs on first page</p>	Apr/09	n/a
			<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>• as second line treatment (after failure of cytokine therapy) for advanced/Metastatic renal cell carcinoma</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b>                      Dr. Tina Cheng, Dr. Bernie Eigl, Dr. D. Heng,                      Dr. Dean Ruether, Dr. Mike Vickers</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. David Holland</p> <p><b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. M. Trudeau</p> <p><b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Oct/09	n/a
STREPTOZOCIN	1	injectable		May/85	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SUNITINIB	2	capsule	<p><b>Musculoskeletal</b></p> <ul style="list-style-type: none"> <li>• Metastatic or unresectable Gastrointestinal Stromal Tumour (GIST) after disease progression on or after intolerance to imatinib</li> <li>• Prescribing limited to written authorization by named physicians:  <b>CCI</b>                      Dr. Quincy Chu, Dr. Karen Mulder, Dr. Robert Turner  <b>TBCC</b>                      Dr. Vivian Bramwell, Dr. Don Morris, Dr. Mike Vickers  <b>Medicine Hat</b>                      Dr. M. Trudeau  <b>Lethbridge</b>                      Dr. D. Holland  <b>Red Deer</b>                      Dr. Callisto Tarukandirwa                      As recommended by the musculoskeletal tumour program or outlined under group 2 drugs on first page.</li> </ul>	Oct/07	n/a
			<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>• First line in advanced/metastatic renal cell carcinoma or second line after interferon failure/intolerance.</li> <li>• Prescribing limited to written authorization by named physicians:  <b>CCI</b>                      Dr. Scott North, Dr. Peter Venner  <b>TBCC</b>                      Dr. Tina Cheng, Dr. Bernie Eigl, Dr. D. Heng,                      Dr. Dean Ruether, Dr. Mike Vickers  <b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke  <b>Lethbridge</b>                      Dr. David Holland  <b>Medicine Hat</b>                      Dr. Jay Easaw, Dr. M. Trudeau  <b>Red Deer</b>                      Dr. Neil Graham, Dr. Callisto Tarukandirwa                      As recommended by the GU tumour program or outlined under group 2 drugs on first page.</li> </ul>	Feb/08	n/a
TAMOXIFEN	1	tablets		Jul/92	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TEMOZOLOMIDE	2	oral	<p><b>NeuroOncology and Pediatrics</b></p> <ul style="list-style-type: none"> <li>• First-line concurrent (with RT)/adjuvant treatment for malignant glioma</li> <li>• First-line treatment of recurrent glioblastoma multiforme and anaplastic astrocytoma.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dorcas Fulton, Dr. Albert Murtha, Dr. Wilson Roa</p> <p><b>TBCC</b> Dr. J.G. Cairncross, Dr. Jay Easaw, Dr. Peter Forsyth, Dr. Don Morris, Dr. Alexander Paterson, As recommended by the neuro oncology tumour program or outlined under group 2 drugs on first page.</p> <p>Or</p> <p><b>CCI</b> Dr. Sunil Desai, Dr. Paul Grundy, Dr. M. Spavor, Dr. Kent Stobart, Dr. Beverly Wilson</p> <p><b>TBCC</b> Dr. Ron A. Anderson, Dr. G. Guilcher, Dr. L. Lafay-Cousin, Dr. Victor Lewis, Dr. Aru Narendran, Dr. Douglas Strother As recommended by the pediatric tumour program or outlined under group 2 drugs on first page.</p>	Sept/04 Feb/00	n/a
	3	oral	<p><b>Pediatrics</b></p> <ul style="list-style-type: none"> <li>• Phase III study of irinotecan and temozolomide in children with recurrent neuroblastoma (protocol ANBL0421)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Sunil Desai, Dr. Paul Grundy, Dr. M. Spavor, Dr. Kent Stobart, Dr. Beverly Wilson</p> <p><b>TBCC</b> Dr. Ron A. Anderson, Dr. G. Guilcher, Dr. L. Lafay-Cousin, Dr. Victor Lewis, Dr. Aru Narendran, Dr. Douglas Strother, As recommended by the pediatric tumour program.</p>	Jan/08	n/a
TENIPOSIDE	1	injectable		May/85	IV inf. – basic
THIOGUANINE	1	tablets			n/a
TOPOTECAN	2	injectable		Jul/97 Apr/09	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB	2	injectable	<p><b>Metastatic Breast</b></p> <ul style="list-style-type: none"> <li>Restricted to the treatment of metastatic breast cancer, HER 2 protein overexpression (+3) by IHC or HER2 amplification by FISH.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b> Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Patterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thaeil, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jan/00 Feb/02 Nov/03	IV load dose - advanced  IV maintenance (2mg/kg weekly or 6mg/kg every 3 weeks) – basic
			<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>Adjuvant/Neoadjuvant treatment of Stage 1-3, HER-2 positive breast cancer for use with or following chemotherapy</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. David Fenton, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Andrew Scarfe, Dr. Katia Tonkin</p> <p><b>TBCC</b> Dr. Walter Blahey, Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. Bruce Keith (May 31, 2010 - October 1, 2010), Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Don Morris, Dr. Alexander Patterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Patricia Tang, Dr. Ted Thaeil, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. David Holland</p> <p><b>Medicine Hat</b> Dr. Jay Easaw, Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Aug/06	Basic
TRETINOIN	2	capsules		May/95 Apr/09	n/a
VINBLASTINE	1	injectable			IV push - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
VINCRIStINE	1	injectable			IV push – basic
VINOReLBINE	2	injectable		Jul/95 Apr/09	IV inf. - basic